Menabitan

Menabitan

Systematic (IUPAC) name
[5,5-dimethyl-8-(3-methyloctan-2-yl)-2-prop-2-ynyl-3,4-dihydro-1H-chromeno[4,3-c]pyridin-10-yl] 2-methyl-4-(2-methylpiperidin-1-yl)butanoate
Clinical data
Legal status	Equivalent of a Schedule I drug via the Federal Analogue Act
Identifiers
CAS Number	83784-21-8 Template:CAS (HCl)
ATC code	None
PubChem	CID: 189877
ChemSpider	164903
Chemical data
Formula	C37H56N2O3
Molecular mass	576.85214 g/mol
SMILES CCCCCC(C)C(C)C1=CC2=C(C3=C(CCN(C3)CC#C)C(O2)(C)C)C(=C1)OC(=O)C(C)CCN4CCCCC4C
InChI InChI=1S/C37H56N2O3/c1-9-11-12-15-26(3)29(6)30-23-33(41-36(40)27(4)17-22-39-20-14-13-16-28(39)5)35-31-25-38(19-10-2)21-18-32(31)37(7,8)42-34(35)24-30/h2,23-24,26-29H,9,11-22,25H2,1,3-8H3 Key:ZWLPJYVIMWAEDC-UHFFFAOYSA-N

Menabitan (INN; SP-204), or menabitan hydrochloride (USAN), is a synthetic drug which acts as a potent cannabinoid receptor agonist. It is closely related to natural cannabinoids of the tetrahydrocannabinol (THC) group, differing mainly by its longer and branched side chain, and the replacement of the 9-position carbon with a nitrogen. It was studied as an analgesic in the 1970s and was found to possess antinociceptive effects in both humans and animals but was never marketed.

Due to its structural similarity to the schedule I/III drug THC it can be treated as a schedule I drug within the United States legal system under the Federal Analogue Act.

See also

• A-40174 (SP-1)
• Dimethylheptylpyran